QCM
AVIR icon

Quantinno Capital Management’s Atea Pharmaceuticals AVIR Stock Holding History

Quantinno Capital Management’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.13M Buy
242,302
+226,352
+1,419% +$1.13M ﹤0.01% 2460
2026
Q1 		$85.8K Buy
+15,950
New +$73.3K ﹤0.01% 3266

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Quantinno Capital Management's AVIR Position: Q2 2026 in Review

Quantinno Capital Management increased its Atea Pharmaceuticals (AVIR) stake by 1,419% in Q2 2026, buying an estimated $1.13M and bringing the position to 242,302 shares worth $1.13M. The position accounts for ﹤0.01% of the portfolio, ranked #2460.

Quantinno Capital Management first reported a position in AVIR in Q1 2026 and has held it in 2 quarters since. 125 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

  • Quantinno Capital Management held 242,302 shares of Atea Pharmaceuticals worth $1.13M as of Q2 2026.
  • Quantinno Capital Management bought 226,352 Atea Pharmaceuticals shares in Q2 2026, an estimated $1.13M.
  • Atea Pharmaceuticals made up ﹤0.01% of Quantinno Capital Management's portfolio in Q2 2026, its #2460 holding.
  • Quantinno Capital Management first reported a position in Atea Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 125 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on Quantinno Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.